J. Goldman & CO LP Moon Lake Immunotherapeutics Call Options Transaction History
J. Goldman & CO LP
- $3.8 Billion
- Q1 2025
Call Options
1 transactions
Others Institutions Holding MLTX
# of Institutions
161Shares Held
55.3MCall Options Held
481KPut Options Held
229K-
Bvf Inc San Francisco, CA19.8MShares$959 Million33.91% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$412 Million35.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.97MShares$144 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$134 Million1.75% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.48MShares$71.8 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.79B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...